⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TVTX News
Travere Therapeutics, Inc. Common Stock
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
businesswire.com
TVTX
Travere Therapeutics to Participate at Upcoming Investor Conferences
businesswire.com
TVTX
Travere Therapeutics Reports Third Quarter 2025 Financial Results
businesswire.com
TVTX
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
businesswire.com
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
businesswire.com
TVTX
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy USA - English USA - English
prnewswire.com
TVTX
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy USA - English USA - English
prnewswire.com
TVTX
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI ® (sparsentan) in FSGS
businesswire.com
TVTX